Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Bruce Lamb, PhD, received his undergraduate degree in biology at Swarthmore College and his doctoral degree in molecular biology at the University of Pennsylvania in the laboratory of Dr. Davor Solter, where he studied the control of gene expression during early mouse development. Dr. Lamb was subsequently a Postdoctoral Fellow at the Johns Hopkins University School of Medicine in Dr. John Gearhart’s laboratory, where he developed technologies to introduce large genomic regions of DNA into the germline of mice in efforts to create mouse models of the dosage imbalance observed in Down syndrome (human trisomy 21). Dr. Lamb joined the Department of Genetics at Case Western Reserve University in 1996 and moved to the Department of Neurosciences at Cleveland Clinic in 2005.
Dr. Lamb is a member of several grant review panels for the National Institutes of Health and the Alzheimer's Association. In addition, Dr. Lamb reviews manuscripts for numerous scientific journals. Dr. Lamb is also a member of the Professional Advisory Board of the Cleveland Alzheimer's Association chapter and a member of the Scientific Advisory Board of the Alzheimer's Research Forum.
The primary focus of Dr. Lamb's laboratory is to utilize transgenic mice to study the molecular basis of complex human genetic diseases. More specifically, we have developed genetic models of Alzheimer’s disease by introducing different human genes carrying Alzheimer’s disease-causing mutations into mice. Importantly, we have demonstrated that these mice develop numerous biochemical, behavioral and neuropathological features of Alzheimer’s disease. We have been continuing to characterize these mice in terms of numerous molecular biological, biochemical, behavioral and neuropathological criteria that will help us determine the effect of these Alzheimer’s disease gene mutations on in vivo biological function and dysfunction. In addition, we are utilizing the YAC transgenic mice to examine the effect of various modifiers and potential therapies of Alzheimer’s disease in a unique model system.
Alzheimer's Disease, mouse models, genetic modifiers, beta amyloid metabolism
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 3/5/2015, Dr. Lamb has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.